circulation sample

Click here to download the Media Pack.

The power of protein biomarkers

A leading proteomics company has patent-pending technologies used to develop earlier and more accurate screening and diagnostic tests for the detection and treatment of disease.

Originally formed as a medical device company, Power3 Medical Products Inc has developed into an innovative holding company strategically positioned to acquire healthcare and biotechnology assets. In 2004 Power3 purchased the assets and intellectual properties of ProteEx of The Woodlands, TX. The company has established a state-of-the-art proteomics laboratory and developed a proprietary process for the discovery, analysis and identification of proteins.

The most significant accomplishments to date are the development and proof-of-concept for a non-invasive breast cancer test and a blood test for neurodegenerative diseases. In addition, the company specialises in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases. The research platform is centred on the study of proteomics, the science of protein interactions within living cells.

With over 50 combined years of proteomics experience, the company has identified 334 protein biomarkers with the following potential medical applications:

  • Breast cancer
  • Chemotherapeutic drug resistance
  • Alzheimer’s disease
  • Leukemia
  • ALS (Lou Gehrig’s disease)
  • Gastrointestinal disease
  • Parkinson’s disease

These discovered and patent-pending biomarkers solve critical challenges facing pharmaceutical and diagnostic companies and are currently being used to design tests to diagnose diseases and discover targets for new drugs to treat the diseases.

Breakthrough breast cancer test

The breast cancer NAFTest is Power3 Medical’s initial breast cancer product developed in collaboration with a major research institute in Houston, Texas. The test utilises fluids from the breast called nipple aspirates to identify groups of breast cancer proteins. The collection of the nipple aspirate fluid is a non-invasive procedure using a modified breast pump to obtain a drop of fluid from the nipple. The aspirate is analysed to identify the specific breast cancer protein footprints. Power3 believes this test is the first of its type that detects breast cancer earlier than any technologies currently allow. The initial proof of concept has been completed with remarkable effectiveness and sensitivity. Clinical trial preparation is currently underway.

Diagnosing degenerative diseases

The NuroPro blood test is Power3’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of nine proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

The NuroPro test is currently in the development stages. The company has completed proof of concept and first stage of clinical validation studies, with results exceeding expectations. The validation is done in collaboration with Dr Stan Appel, professor of neurology at Baylor College of Medicine.

Drug resistance to chemotherapeutic agents in cancer

Power3 Medical's technology has the potential to be used to develop new drugs based upon the precise differences between diseased-related and healthy-related protein footprints. New drugs can be engineered to hone in on the changed protein structures and alter them. Power3 uses proteomics for the specific identification of proteins involved in a disease to provide usable products to address unmet needs and new treatment options. This platform has specific application in the area of drug resistance to chemotherapeutic agents in cancer. By the time development of resistance to chemotherapeutic agents is detected, it is usually too late to save the patient. Power3’s technology can be used to detect drug resistance before treatment and engineer drugs to kill both sensitive and resistant cancer to prevent recurrence.

The company completed an initial proof of concept that addresses drug resistance to a major chemotherapy agent. Knowing if a cancer patient is sensitive or detecting earlier the development of resistance during treatment could eliminate toxic effects, trial-and-error treatment regimens and save the patient. These findings have the potential to change existing treatment algorithms and will yield significant value. The pharmaceutical industry will then gain the technology to screen patients, on a molecular level, prior to clinical trials and will design new drugs to overcome resistance. Management believes this technology will increase the success rates of chemotherapy agents and eliminate futile treatments early in the clinical trials, saving lives and significant financial resources.

Status of clinical validation trials

Breast cancer
Alzheimer’s disease
Drug resistance
Metabolic syndrome

Multiple sites/ongoing
2Q 2005
4Q 2005
4Q 2005

Investment considerations

The company has an impressive track record to attract potential investors, including:

  • Significant portfolio of 344 identified biomarkers and patents (15 pending and one issued patent)
  • Proprietary protein techniques that yield high-quality, highly-sensitive, reproducible results
  • Over 5O years of combined proteomics experience
  • Technologies/products in large and growing markets
  • Strategically positioned to commercialise technology and become the ‘dominant player’ in the protein-based diagnostic market
  • Significant revenue opportunities from licensing of discovered biomarkers to large diagnostic companies
  • Dedicated management and world-class scientific advisory board

Strategy, partnerships and alliances

The company’s strategy is to capitalise on protein pattern and biomarker discovery, and commercially validate science. Its focus is on development efforts on protein-based early diagnostic tests and the drug target market. Partnerships and alliances include:

  • Research agreement with New Horizons Diagnostics Corporation to develop diagnostic tests for neurodegenerative disease.
  • Two exclusive licensing agreements with University of Texas MD Anderson Cancer Centre to produce, market and sell proteomics technology.
  • Exclusive licensing agreement with Baylor College of Medicine to produce, market and sell technology related to biomarkers of neurodegenerative diseases.
  • Future licensing agreements planned with diagnostic and pharmaceutical companies.

Further information

Power3 Medical Products Inc
Tel: +1 281 446 1600
Tel: +1 281 446 11481



Published by SPG Media Limited
Brunel House 55-57 North Wharf Road, London W2 1LA, UK
Tel: + 44 20 7915 9908
Fax: + 44 20 7915 9773